Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Hand-Held Rx Counterfeit Detector Could Roll Out To Developing Nations

Executive Summary

Agency meets with USAID stakeholders and wants to maximize the public health impact of its hand-held counterfeit drug detection device, which allows for quick preliminary screening of drug shipments to determine if counterfeit or adulterated product is present.

You may also be interested in...



Gottlieb Showing Capitol Hill Skills With Funding Success

US FDA gains $94m in new funding for international mail facilities, a priority for the commissioner, along with an increase in non-user fee dollars for agency operations.

Track-and-Trace Law: Push Begins For 2015 Exchange Standards

FDA has a tight deadline to finalize guidance on transaction information.

FDA Counterfeit Screening Tool Gets Field Test In Ghana; Corning Prepares Device For Mass Production

FDA currently employs the CD3 in its laboratories and at a number of international mail facilities and other points of entry to the U.S. to screen cosmetics, foods, medical devices and cigarettes, as well as drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS055213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel